Clinical experience with active surveillance protocol using regular magnetic resonance imaging instead of regular repeat biopsy for monitoring: A study at a high-volume center in Korea

Mohler, 2019, Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 17, 479, 10.6004/jnccn.2019.0023 Heidenreich, 2011, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease, Eur Urol, 59, 61, 10.1016/j.eururo.2010.10.039 Thompson, 2007, Guideline for the management of clinically localized prostate cancer: 2007 update, J Urol, 177, 2106 Andriole, 2012, Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up, J Natl Cancer Inst, 104, 125, 10.1093/jnci/djr500 Carter, 2002, Expectant management of nonpalpable prostate cancer with curative intent: preliminary results, J Urol, 167, 1231 Dall'Era, 2008, Active surveillance for the management of prostate cancer in a contemporary cohort, Cancer, 112, 2664, 10.1002/cncr.23502 Berglund, 2008, Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance, J Urol, 180, 1964 Soloway, 2008, Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience, BJU Int, 101, 165, 10.1111/j.1464-410X.2007.07190.x Lee, 2012, Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center, Jpn J Clin Oncol, 42, 1079, 10.1093/jjco/hys147 Lee, 2013, Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol, Jpn J Clin Oncol, 43, 553, 10.1093/jjco/hyt041 Lee, 2013, Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis, J Urol, 190, 1213 Lee, 2014, Clinical experiences of incidental prostate cancer after transurethral resection of prostate (TURP) according to initial treatment: a study of a Korean high volume center, Yonsei Med J, 55, 78, 10.3349/ymj.2014.55.1.78 Purysko, 2016, PI-RADS Version 2: A Pictorial Update, Radiographics, 36, 1354, 10.1148/rg.2016150234 Simpkin, 2015, Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer, Eur Urol, 67, 993, 10.1016/j.eururo.2015.01.004 Wilt, 2012, Radical prostatectomy versus observation for localized prostate cancer, N Engl J Med, 367, 203, 10.1056/NEJMoa1113162 Klotz, 2010, Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer, J Clin Oncol, 28, 126, 10.1200/JCO.2009.24.2180 Carter, 2007, Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience, J Urol, 178, 2359 van As, 2008, Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance, Eur Urol, 54, 1297, 10.1016/j.eururo.2008.02.039 Olivier, 2019, Low-risk prostate cancer selected for active surveillance with negative MRI at entry: can repeat biopsies at 1 year be avoided? A pilot study, World J Urol, 37, 253, 10.1007/s00345-018-2420-6 Iremashvili, 2016, Is It Time to Revisit the Role of Prostate-specific Antigen Kinetics in Active Surveillance for Prostate Cancer?, Urology, 95, 139, 10.1016/j.urology.2016.04.016 Gallagher, 2019, Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies, BJU Int, 123, 429, 10.1111/bju.14513 Lee, 2015, Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer, Prostate Int, 3, 127, 10.1016/j.prnil.2015.09.005 Lee, 2017, The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study, Int Urol Nephrol, 49, 2119, 10.1007/s11255-017-1696-6 Park, 2019, The association of family history of prostate cancer with the diagnosis of clinically significant prostate cancer in Korean population, Investig Clin Urol, 60, 442, 10.4111/icu.2019.60.6.442 van den Bergh, 2010, Do anxiety and distress increase during active surveillance for low risk prostate cancer?, J Urol, 183, 1786 Dahabreh, 2012, Active surveillance in men with localized prostate cancer: a systematic review, Ann Intern Med, 156, 582, 10.7326/0003-4819-156-8-201204170-00009 Jones, 2009, Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era, Prostate Cancer Prostatic Dis, 12, 57, 10.1038/pcan.2008.14 Descazeaud, 2008, Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era, Eur Urol, 53, 355, 10.1016/j.eururo.2007.06.020 Herden, 2016, Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study, BJU Int, 118, 258, 10.1111/bju.13308 Bruinsma, 2018, The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date, BJU Int, 121, 737, 10.1111/bju.14106